Vertex (VRTX) CMO Carmen Bozic executes Rule 10b5-1 sale of 2,329 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold common stock in a planned transaction. On February 27, 2026, she completed an open-market sale of 2,329 shares of Vertex common stock at an average price of $480.31 per share. After the sale, she directly owned 37,734 shares. The trade was made under a pre-established Rule 10b5-1 trading plan entered on November 20, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,329 shares ($1,118,642)
Net Sell
1 txn
Insider
Bozic Carmen
Role
EVP and CMO
Sold
2,329 shs ($1.12M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,329 | $480.31 | $1.12M |
Holdings After Transaction:
Common Stock — 37,734 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Vertex (VRTX) EVP and CMO Carmen Bozic report in this Form 4?
Carmen Bozic reported an open-market sale of Vertex common stock. She sold 2,329 shares at an average price of $480.31 per share and continued to hold 37,734 shares directly after the transaction, according to the Form 4 disclosure.
Was the Vertex (VRTX) insider sale by Carmen Bozic under a Rule 10b5-1 plan?
Yes, the transaction was executed under a company-approved Rule 10b5-1 trading plan. The footnote states the plan was entered into on November 20, 2025, and the February 27, 2026 sale was carried out pursuant to that pre-arranged plan.
What transaction code is used for Carmen Bozic’s Vertex (VRTX) stock sale?
The filing uses transaction code “S” for the stock sale. This code indicates a sale in the open market or a private transaction, which in this case is described as an open-market sale of Vertex common stock.